Rapt Therapeutics (RAPT) to Release Earnings on Thursday

Rapt Therapeutics (NASDAQ:RAPT) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.92) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Rapt Therapeutics Stock Performance

RAPT stock opened at $57.96 on Thursday. The company’s fifty day moving average price is $46.76 and its 200-day moving average price is $32.20. Rapt Therapeutics has a one year low of $5.67 and a one year high of $57.98. The company has a market capitalization of $1.61 billion, a PE ratio of -5.24 and a beta of 0.47.

Wall Street Analysts Forecast Growth

RAPT has been the topic of several research analyst reports. Wells Fargo & Company downgraded shares of Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price objective for the company. in a report on Tuesday, January 20th. Barclays lowered Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price target for the company. in a research note on Wednesday, January 21st. Piper Sandler cut Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price target for the company. in a report on Tuesday, January 20th. HC Wainwright cut Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a report on Tuesday, January 20th. Finally, Guggenheim downgraded Rapt Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Rapt Therapeutics currently has an average rating of “Hold” and a consensus price target of $48.44.

Institutional Trading of Rapt Therapeutics

A number of institutional investors have recently bought and sold shares of RAPT. Invesco Ltd. raised its stake in shares of Rapt Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after acquiring an additional 47,391 shares during the period. AQR Capital Management LLC bought a new position in Rapt Therapeutics during the 1st quarter valued at about $188,000. Dimensional Fund Advisors LP bought a new position in Rapt Therapeutics during the 3rd quarter valued at about $231,000. UBS Group AG raised its position in Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after purchasing an additional 25,116 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in Rapt Therapeutics by 32.0% in the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after purchasing an additional 5,000 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.